Table 1.
Phase III HS therapeutic pipeline discussed at the 2026 AAD annual meeting
| Agent | Mechanism/target | Route of administration | Trial phase and status* | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Lutikizumab | IL-1α/IL-1β inhibitor | Subcutaneous | Phase III (recruiting) | NCT06468228 |
| Povorcitinib | Selective JAK1 inhibitor | Oral | Phase III (completed) | |
| Remibrutinib | BTK inhibitor | Oral | Phase III (ongoing) | NCT06840392 |
| Ruxolitinib | JAK1/2 inhibitor | Topical | Phase III (recruiting) | |
| Sonelokimab | IL-17A/F inhibitor | Subcutaneous | Phase III (completed) | |
| Spesolimab | IL-36 receptor inhibitor | Intravenous and subcutaneous | Phase IIb/III (completed) | NCT05819398 |
| Upadacitinib | Selective JAK1 inhibitor | Oral | Phase III (recruiting) | NCT05889182 |
*Status reported as of June 2026
BAFF B-cell activating factor, BTK Bruton’s tyrosine kinase, IL interleukin, JAK Janus kinase, OX40L OX40 ligand, TNF-α tumor necrosis factor-alpha